Bulletin
Investor Alert

July 14, 2020, 7:15 a.m. EDT

Electromedical Technologies Q1 Revenues Increase 22%; Innovative DeepPulse(TM) and WellnessPro Plus(R) Targets A $44 Billion Pain-Management Treatment Market Opportunity

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Earlier this year, Electromedical announced that it has joined into a collaborative agreement with Nazarbayev University, Nur-Sultan, Kazakhstan. The comprehensive research program will evaluate the effects of electro-modulation on the human body's physiological state by studying the impacts of alternating electrical fields on cell signaling. The research may expand toward electro-modulation studies to explore the possibility of frequencies interfering with replication and assembly of large single-stranded RNA viruses. The plan is for the team to create a variety of laboratory conditions where they can test virus responses, hoping that a virus can be inactivated or, at the least, minimize its pathogenic capacity.

Additional support for the emerging bioelectric field came in a 2019 front-page article published in TIME magazine. The report pointed to the convergence of advances in bioengineering and neurology, which has resulted in a fast-developing way of treating chronic diseases, known as bioelectronic medicine. These ground-breaking advances allow scientists to identify specific nerves and then implant devices that can be activated when needed to stimulate or dial down their activity. The data shows that these devices can, in turn, help to control cells in organs targeted by those nerves that regulate the body's many immune and metabolic responses. The author noted a belief that bioelectronics will one day stand alongside pharmaceuticals to help improve human health.

Life-Changing Products Create A Value Opportunity

Electromedical Technologies is delivering innovative and useful life-changing products to the market. They also recognize that healthcare is a human business, something that will never go out of style. It's their philosophy and market expertise that can drive long-term shareholder value.

Further, Electromedical Technologies has the knowledge, product line, financial means, and management to deliver to market their innovative non-toxic, non-invasive bioelectronic solutions. The company added a key person to its advisory team by announcing that Constantin Kishkovski has been appointed to the Company's Marketing Advisory Board to help the company prepare for European expansion. Constantin Kishkovski was formerly Head of The Representative Office in the Ukraine of the Medical and Consumer Divisions for Johnson and Johnson (NYSE: JNJ ). Also, Mr. Kishkovski was Director of Sales for Nestle Inc. (OTC: NSRGY) in the Ukraine and Moldova.

His vision may add to a strategy that must address a "New Normal" when it comes to daily life. It's believed that because of the pandemic, more and more people will be looking towards telemedicine and treatments at home, and millions more who find themselves in lockdown and struggling with chronic pain and opioid abuse may find limited treatment options. WellnessPro® Plus may be a logical choice for people needing constant care.

WellnessPro® technology has helped thousands of people relieve their chronic pain and achieve a better quality of life without toxic side effects or drug interactions. And, their DeepPulse™ technology is making their products even better.

Innovation breeds success. And, Electromedical Technologies is leveraging its status as an industry leader and pioneer toward the future of bioelectric treatment. It's a position that can deliver both near and long-term rewards for the company and its user-patients.

Disclaimer

This communication was produced by PCG Digital Holdings, LLC, and affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures

Media Contact
Company Name: PCG Digital Holdings
Contact Person: Kenny Ellis
Email: Send Email
City: New York
State: New York
Country: United States
Website: https://pcgadvisory.com/



COMTEX_368035071/2555/2020-07-14T07:14:44

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.